|Pronunciation||flor tau' si pir 18 F|
|Other names||18F-AV-1451, 18F-AV-1451, 18F-T807, Flortaucipir F-18, flortaucipir F 18 (USAN US)|
|Chemical and physical data|
|Molar mass||262.27 g/mol|
|3D model (JSmol)|
Two proteins – tau and amyloid – are recognized as hallmarks of Alzheimer's disease. In people with Alzheimer's disease, pathological forms of tau proteins develop inside neurons in the brain, creating neurofibrillary tangles. After flortaucipir (18F) is administered intravenously, it binds to sites in the brain associated with this tau protein misfolding. The brain can then be imaged with a PET scan to help identify the presence of tau pathology.
It is the first drug used to help image a distinctive characteristic of Alzheimer's disease in the brain called tau pathology. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Flortaucipir (18F) is a radioactive diagnostic agent for adults with cognitive impairment who are being evaluated for Alzheimer's disease. It is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs), a primary marker of Alzheimer's disease.
Chemically, flortaucipir F 18 is 7-(6-[F-18]fluoropyridin-3-yl)-5H-pyrido[4,3 b]indole.
The safety and effectiveness of flortaucipir (18F) imaging was evaluated in two clinical studies. In each study, five evaluators read and interpreted the flortaucipir (18F) imaging. The evaluators were blinded to clinical information and interpreted the imaging as positive or negative.
The first study enrolled 156 participants who were terminally ill and agreed to undergo flortaucipir (18F) imaging and participate in a post-mortem brain donation program. In 64 of the participants who died within nine months of the flortaucipir (18F) brain scan, evaluators' reading of the flortaucipir (18F) scan was compared to post-mortem readings from independent pathologists who evaluated the density and distribution of neurofibrillary tangles (NFTs) in the same brain. The study showed evaluators reading the flortaucipir (18F) images had a high probability of correctly evaluating participants with tau pathology and had an average-to-high probability of correctly evaluating participants without tau pathology.
The second study included the same participants with terminal illness as the first study, plus 18 additional participants with terminal illness, and 159 participants with cognitive impairment being evaluated for Alzheimer's disease (the indicated patient population). The study gauged how well flortaucipir (18F) evaluators' readings agreed with each other's assessments of the readings. Perfect reader agreement would be 1, while no reader agreement would be 0. In this study, reader agreement was 0.87 across all 241 participants. In a separate subgroup analysis that included the 82 terminally ill participants diagnosed after death and the 159 participants with cognitive impairment, reader agreement was 0.90 for the participants in the indicated population and 0.82 in the terminally ill participants.
The FDA approved flortaucipir (18F) based on evidence of 1921 participants from 19 trials conducted at 322 sites in the United States, Australia, Belgium, Canada, France, Japan, Netherlands and Poland.
The ability of flortaucipir (18F) to detect tau pathology was assessed in participants with generally severe stages of dementia and may be lower in participants in earlier stages of cognitive decline than in the participants with terminal illness who were studied.
- "Tauvid- flortaucipir f-18 injection, solution". DailyMed. 22 July 2020. Retrieved 28 May 2022.
- "FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer's Disease". U.S. Food and Drug Administration (FDA) (Press release). 28 May 2020. Retrieved 28 May 2020. This article incorporates text from this source, which is in the public domain.
- "Drug Trial Snapshot: Tauvid". U.S. Food and Drug Administration (FDA). 28 May 2020. Retrieved 10 June 2020. This article incorporates text from this source, which is in the public domain.
- "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
- "Lilly Receives U.S. FDA Approval of Tauvid (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease" (Press release). Eli Lilly. 28 May 2020. Retrieved 28 May 2020 – via PR Newswire.
- "Drug Approval Package: Tauvid". U.S. Food and Drug Administration (FDA). 16 July 2020. Retrieved 28 May 2022.
- World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.
- Pontecorvo MJ, Devous MD, Kennedy I, et al. (June 2019). "A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia". Brain. 142 (6): 1723–1735. doi:10.1093/brain/awz090. PMC 6536847. PMID 31009046.
- Schonhaut DR, McMillan CT, Spina S, et al. (October 2017). "18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study". Ann. Neurol. 82 (4): 622–634. doi:10.1002/ana.25060. PMC 5665658. PMID 28980714.
- "Flortaucipir F18". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03507257 for "Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS)" at ClinicalTrials.gov
- Clinical trial number NCT02278367 for "Clinical Evaluation of 18F-AV-1451" at ClinicalTrials.gov
- Clinical trial number NCT02516046 for "18F-AV-1451 Autopsy Study" at ClinicalTrials.gov
- Clinical trial number NCT03901092 for "A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation" at ClinicalTrials.gov